Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06167291
Other study ID # 2022-0915
Secondary ID NCI-2023-10400
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 19, 2024
Est. completion date December 9, 2027

Study information

Verified date April 2024
Source M.D. Anderson Cancer Center
Contact David Rosenthal, MD
Phone (713) 563-2353
Email dirosenthal@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck. However, for participants with oropharyngeal cancer on one side of the neck, receiving radiation to both sides of the neck may result in increased side effects and radiation exposure. This study is testing the safety and effectiveness of an approach that involves radiation to only one side of the neck in an effort to reduce the overall amount of radiation given and decrease the amount of side effects you may experience.


Description:

Primary Objectives To determine whether: 1. Omission of the contralateral neck cancer treatment is safe and toxicity-sparing for participants with well lateralized oropharyngeal HNSCC undergoing definitive or PORT radiation. This will be demonstrated by acceptably low contralateral neck failures (<15%) Secondary Objectives To determine: 1. the relative difference in symptom burden, as measured by the MDASI_HN area-under-the-toxicity curve (AUC), for initial surgical and initial non-surgical therapy cohorts. 2. Whether omission of the contralateral neck in radiotherapy planning as definitive of PORT treatment for well-lateralized oropharyngeal tumors will impact symptom burden as measured by MDASI AUC, Grade 2 or higher CTCAE v5.0 toxicity, swallow function, and/or feeding tube rates and dependency. 3. Risk adapted therapy approaches lead to differences in distant-metastasis-free survival (DMFS), ipsilateral neck failure, primary site failure, and whether salvage therapy for contralateral neck failures is feasible and effective compared to historical controls.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date December 9, 2027
Est. primary completion date December 9, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Newly diagnosed histopathologically-proven p16+ and/or HPV+ HNSCC of the base of tongue or faucial tonsil - cT1-2N0-1 per AJCC 8th edition staging. - Tumor does not cross midline, and must be >1cm from midline - For tonsil tumors, the primary may extend onto the palate or into the BOT but still be >1cm from midline - No evidence of contralateral neck disease on contrast MRI, CT Head/Neck, PET/CT, or lymphoscintigraphy nor retropharyngeal lymphadenopathy. - Able to undergo lymphoscintigraphy procedure - No contraindications for SLNM, adjuvant chemotherapy, RT nor adjuvant/definitive radiotherapy. - ECOG 0-1 - Age >18 years - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria - Previous HN Cancer except small skin cancers. - Any retropharyngeal lymphadenopathy on either MRI, CT, or PET/CT - Contralateral neck nodal disease radiographically detected per routine diagnostic imaging or SPECT-CT. - Distant metastatic spread at the time of inclusion - Chemotherapy or surgery (for the present tumor), prior to inclusion. - Previous radiation treatment in the head and neck region, for any reason, except for cutaneous lesions that would not lead to overlap with definitive bilateral neck irradiation - Previous thyroidectomy or neck dissection (causes aberrant nodal drainage) - Recurrent or second primary tumor in the head and neck region - Non-tongue base or non-faucial tonsil primaries - Prior history of regionally advanced or distant spread cancers - Pregnancy or no active contraception for pre-menopausal women - Known hypersensitivity to iodine or nanocolloid injection - Having any condition (physical, mental, sociological) that interferes with the informed consent procedure and follow-up schedules Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Arm 1- Ipsilateral
Given by I-RT

Locations

Country Name City State
United States MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and adverse events (AEs) Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 Through study completion; an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT03239834 - Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Recruiting NCT00251381 - Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. Phase 2
Completed NCT03074110 - Isocapnic Hyperventilation - an Alternative Method N/A
Enrolling by invitation NCT04266093 - Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Recruiting NCT02792322 - Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck N/A
Active, not recruiting NCT00918710 - Human Papillomavirus and Oropharynx Carcinoma N/A
Recruiting NCT05412628 - Investigating the Association Between Microbiota and Esophageal/Oropharyngeal Cancer N/A
Recruiting NCT04124198 - Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma N/A
Completed NCT00721799 - F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients Phase 2
Recruiting NCT00181038 - Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Phase 3
Terminated NCT04015336 - E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer Phase 2
Withdrawn NCT04044950 - A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer Phase 2
Completed NCT02262247 - A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures N/A
Terminated NCT01687413 - Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Phase 3
Completed NCT01530997 - De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca Phase 2
Completed NCT03010813 - A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery N/A
Completed NCT03077243 - P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC Phase 2
Terminated NCT02045186 - Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) N/A
Withdrawn NCT02298595 - Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT02281955 - De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study Phase 2

External Links